New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double‐Blind, Parallel‐Group, Single‐Dose Trial in Healthy Subjects
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1473 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Sigrid Balser und 5 weiteren Autor:innen. Beteiligte Einrichtung: Formycon AG, Martinsried/Planegg, Germany. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Ustekinumab, Therapeutic Equivalency, Healthy Volunteers. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In the RUSTIC trial, pharmacokinetic (PK) similarity between the proposed ustekinumab biosimilar FYB202 and EU‐approved (EU‐Ref) and US‐licensed ustekinumab (US‐Ref) as well as between both reference drugs was assessed after a single 45‐mg subcutaneous injection. Safety analyses comprised immunogenicity (antidrug antibodies, neutralizing antibodies), adverse events, and local tolerability. Overall, 491 healthy adults were randomized 1:1:1 and observed for up to 112 days; 486 completed the trial, and 478 were included in the PK analysis. All 3 comparisons showed PK similarity, since the 90% confidence intervals of the respective geometric mean ratios for area under the concentration‐time curve from time 0 to infinity and maximum serum concentration were contained within the acceptance interval of 80%‐125%. No clinically meaningful differences regarding overall safety, immunogenicity, and local tolerability were observed. Notably, after FYB202 administration, in fewer subjects at least 1 positive antidrug antibody result was observed compared to the reference groups (FYB202, 20%; EU‐Ref, 42%; US‐Ref, 51%). In conclusion, the RUSTIC trial demonstrated equivalent PK characteristics for FYB202 when compared to both EU‐Ref and US‐Ref ustekinumab and between both reference drugs. It provides the basis for the marketing authorization of FYB202, together with an extensive analytical characterization and the results of a confirmatory efficacy and safety trial in patients with moderate to severe plaque psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Formycon AG, Martinsried/Planegg, Germany.
- SocraTec R&D GmbH, Oberursel/Erfurt, Germany.
- SocraMetrics GmbH, Erfurt, Germany.
Zitieren
APA
Balser, S., Nopora, K., Körner, J., Wedemeyer, R. S., Anschütz, M., & Schug, B. (2024). New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double‐Blind, Parallel‐Group, Single‐Dose Trial in Healthy Subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1473
Vancouver
Balser S, Nopora K, Körner J, Wedemeyer RS, Anschütz M, Schug B. New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double‐Blind, Parallel‐Group, Single‐Dose Trial in Healthy Subjects. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1473
BibTeX
@article{Balser2024,
author = {Balser, Sigrid and Nopora, Katrin and Körner, Juliane and Wedemeyer, Ralph-Steven and Anschütz, Maria and Schug, Barbara},
title = {New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double‐Blind, Parallel‐Group, Single‐Dose Trial in Healthy Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1473}
}
EUVIMED